Sun Pharma Q3 PAT seen up 56.7% YoY to Rs. 1,431.5 cr: Yash Securities
Net Sales are expected to increase by 7.7 percent Y-o-Y (up 2.7 percent Q-o-Q) to Rs. 8,782.1 crore, according to Yash Securities.22-01-2021
22-01-2021
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Corporate Action-Board to consider Dividend
The Board of Directors of the Company, at its meeting scheduled to be held on Friday, January 29, 2021, will inter-alia consider declaration of Interim Dividend on the equity shares of the Company, for the financial year 2020-2121-01-2021
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Statement Of Investor Complaints For The Quarter Ended December 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0110 Name of the Signatory :- Ashok BhutaDesignation :- Any Other19-01-2021
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Shareholding for the Period Ended December 31, 2020
Sun Pharmaceutical Industries Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2020. For more details, kindly Click here19-01-2021
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Please find enclosed intimation for issue of Duplicate Share Certificate15-01-2021
Bright outlook: Sun Pharma to Cipla, drug firms set for Q3 health boost
Analysts expect earnings growth to be in the range of 30-40 per cent for drug firms owing to both domestic recovery as well as strong export opportunities11-01-2021
Sun Pharma rises 3%, hits over 2-year high on steady earnings visibility
The board of directors of Sun Pharma are scheduled to meet on January 29, 2021 to consider and approve Q3 results08-01-2021
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find enclosed Certificate under Reg 74(5) of SEBI (DP) Regulatons, 201807-01-2021
Sun Pharma starts phase 2 trial for drug to treat plaque psoriasis
Sun Pharma on Monday said it has initiated Phase 2 clinical trial for a product being developed to treat patients with moderate to severe plaque psoriasis.04-01-2021
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release relating to initiation of Phase 2 clinical trial of SCD-044 in patients with moderate to severe plaque psoriasis04-01-2021